Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis

Completed

Conditions studied: Systemic Sclerosis

In brief

This study is to determine if subjects with .systemic sclerosis have stimulatory autoantibodies to the PDGF receptor and to confirm activation (phosphorylation) of the PDGF receptor in skin sites with varying degrees of skin thickening

Key facts

Study ID

NCT00667134

Run by

University of Michigan

People needed

26

Starts

2008-03-01

Expected to finish

2012-02-01

Last updated by the study team

2016-10-26

Who can join

Age: 18 and older, up to 99. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Fulfill the American College of Rheumatology criteria for systemic sclerosis or:
• Have no diseases that result in primary fibrosis of an organ system, including the skin and do not have an autoimmune disease

You may not qualify if…

• If the subject has systemic sclerosis resulting from an environmental exposure
• If the subject has an autoimmune disease excluding scleroderma
• If the subject has an active infection (including, but not limited to hepatitis B, hepatitis C and HIV)
• If the subject has been treated with cyclophosphamide in the past 8 weeks.
• If the subject is prone to bleeding because they are on medications that thin the blood or have a low platelet count.

Where it is running

• University of Michigan Medical School — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.